|
1
|
Stiegelbauer V, Perakis S, Deutsch A, Ling
H, Gerger A and Pichler M: MicroRNAs as novel predictive biomarkers
and therapeutic targets in colorectal cancer. World J
Gastroenterol. 20:11727–11735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 5:2974–2987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang HZ, Ma Y, Zhou Y, Xu LM, Chen XJ,
Ding WB and Zou HB: Autophagy contributes to the enrichment and
survival of colorectal cancer stem cells under oxaliplatin
treatment. Cancer Lett. 361:128–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shi Y, Han Y, Xie F, Wang A, Feng X, Li N,
Guo H and Chen D: ASPP2 enhances oxaliplatin (L-OHP)-induced
colorectal cancer cell apoptosis in a p53-independent manner by
inhibiting cell autophagy. J Cell Mol Med. 19:535–543. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu W, Zhang Z, Zhang Y, Chen X, Guo S,
Lei Y, Xu Y, Ji C, Bi Z and Wang K: HMGB1-mediated autophagy
modulates sensitivity of colorectal cancer cells to oxaliplatin via
MEK/ERK signaling pathway. Cancer Biol Ther. 16:511–517. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xie L, Jing R, Qi J, Lin Z and Ju S: Drug
resistance-related microRNAs in hematological malignancies:
Translating basic evidence into therapeutic strategies. Blood Rev.
29:33–44. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taniguchi K, Sugito N, Kumazaki M,
Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama
K, et al: MicroRNA-124 inhibits cancer cell growth through
PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett.
363:17–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong X, Xiao Y, Chen C, Wei X, Hu C, Ling
X and Liu X: MicroRNA-203-mediated posttranscriptional deregulation
of CPEB4 contributes to colorectal cancer progression. Biochem
Biophys Res Commun. 466:206–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao
X, Jia W and Huang J: Decreased expression of miR-218 is associated
with poor prognosis in patients with colorectal cancer. Int J Clin
Exp Pathol. 6:2904–2911. 2013.PubMed/NCBI
|
|
11
|
Fischer U, Heckel D, Michel A, Janka M,
Hulsebos T and Meese E: Cloning of a novel transcription
factor-like gene amplified in human glioma including astrocytoma
grade I. Hum Mol Genet. 6:1817–1822. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tao K, Yang J, Hu Y and Deng A: Knockdown
of YEATS4 inhibits colorectal cancer cell proliferation and induces
apoptosis. Am J Transl Res. 7:616–623. 2015.PubMed/NCBI
|
|
13
|
Kim YR, Park MS, Eum KH, Kim J, Lee JW,
Bae T, Lee DH and Choi JW: Transcriptome analysis indicates TFEB1
and YEATS4 as regulatory transcription factors for drug resistance
of ovarian cancer. Oncotarget. 6:31030–31038. 2015.PubMed/NCBI
|
|
14
|
Wei MF, Chen MW, Chen KC, Lou PJ, Lin SY,
Hung SC, Hsiao M, Yao CJ and Shieh MJ: Autophagy promotes
resistance to photodynamic therapy-induced apoptosis selectively in
colorectal cancer stem-like cells. Autophagy. 10:1179–1192. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang ZJ, Chee CE, Huang S and Sinicrope
FA: The role of autophagy in cancer: Therapeutic implications. Mol
Cancer Ther. 10:1533–1541. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stanton MJ, Dutta S, Zhang H, Polavaram
NS, Leontovich AA, Hönscheid P, Sinicrope FA, Tindall DJ, Muders MH
and Datta K: Autophagy control by the VEGF-C/NRP-2 axis in cancer
and its implication for treatment resistance. Cancer Res.
73:160–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mizushima N, Yoshimori T and Levine B:
Methods in mammalian autophagy research. Cell. 140:313–326. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang KY, Ma J, Zhang FX, Yu MJ, Xue JS and
Zhao JS: MicroRNA-378 inhibits cell growth and enhances
L-OHP-induced apoptosis in human colorectal cancer. IUBMB Life.
66:645–654. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Faltejskova P, Besse A, Sevcikova S,
Kubiczkova L, Svoboda M, Smarda J, Kiss I, Vyzula R and Slaby O:
Clinical correlations of miR-21 expression in colorectal cancer
patients and effects of its inhibition on DLD1 colon cancer cells.
Int J Colorectal Dis. 27:1401–1408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu K, Liang X, Shen K, Sun L, Cui D, Zhao
Y, Tian J, Ni L and Liu J: MiR-222 modulates multidrug resistance
in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell
Res. 318:2168–2177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao X and Jin W: The emerging role of
tumor-suppressive microRNA-218 in targeting glioblastoma stemness.
Cancer Lett. 353:25–31. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alajez NM, Lenarduzzi M, Ito E, Hui AB,
Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, et al: MiR-218
suppresses nasopharyngeal cancer progression through downregulation
of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71:2381–2391.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zarogoulidis P, Petanidis S, Kioseoglou E,
Domvri K, Anestakis D and Zarogoulidis K: MiR-205 and miR-218
expression is associated with carboplatin chemoresistance and
regulation of apoptosis via Mcl-1 and Survivin in lung cancer
cells. Cell Signal. 27:1576–1588. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan
FK, Sung JJ and Yu J: MicroRNA-218 inhibits cell cycle progression
and promotes apoptosis in colon cancer by downregulating BMI1
polycomb ring finger oncogene. Mol Med. 18:1491–1498.
2013.PubMed/NCBI
|
|
25
|
Zhang XL, Shi HJ, Wang JP, Tang HS and Cui
SZ: MiR-218 inhibits multidrug resistance (MDR) of gastric cancer
cells by targeting Hedgehog/smoothened. Int J Clin Exp Pathol.
8:6397–6406. 2015.PubMed/NCBI
|
|
26
|
Yamamoto N, Kinoshita T, Nohata N, Itesako
T, Yoshino H, Enokida H, Nakagawa M, Shozu M and Seki N: Tumor
suppressive microRNA-218 inhibits cancer cell migration and
invasion by targeting focal adhesion pathways in cervical squamous
cell carcinoma. Int J Oncol. 42:1523–1532. 2013.PubMed/NCBI
|
|
27
|
Hu Y, Xu K and Yagüe E: miR-218 targets
survivin and regulates resistance to chemotherapeutics in breast
cancer. Breast Cancer Res Treat. 151:269–280. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pikor LA, Lockwood WW, Thu KL, Vucic EA,
Chari R, Gazdar AF, Lam S and Lam WL: YEATS4 is a novel oncogene
amplified in non-small cell lung cancer that regulates the p53
pathway. Cancer Res. 73:7301–7312. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fischer U, Meltzer P and Meese E: Twelve
amplified and expressed genes localized in a single domain in
glioma. Hum Genet. 98:625–628. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barretina J, Taylor BS, Banerji S, Ramos
AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho
A, et al: Subtype-specific genomic alterations define new targets
for soft-tissue sarcoma therapy. Nat Genet. 42:715–721. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li PL, Zhang X, Wang LL, Du LT, Yang YM,
Li J and Wang CX: MicroRNA-218 is a prognostic indicator in
colorectal cancer and enhances 5-fluorouracil-induced apoptosis by
targeting BIRC5. Carcinogenesis. 36:1484–1493. 2015.PubMed/NCBI
|
|
32
|
Park JH and Roeder RG: GAS41 is required
for repression of the p53 tumor suppressor pathway during normal
cellular proliferation. Mol Cell Biol. 26:4006–4016. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carro MS, Lim WK, Alvarez MJ, Bollo RJ,
Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, et al:
The transcriptional network for mesenchymal transformation of brain
tumours. Nature. 463:318–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sui X, Chen R, Wang Z, Huang Z, Kong N,
Zhang M, Han W, Lou F, Yang J, Zhang Q, et al: Autophagy and
chemotherapy resistance: A promising therapeutic target for cancer
treatment. Cell Death Dis. 4:e8382013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mikhaylova O, Stratton Y, Hall D, Kellner
E, Ehmer B, Drew AF, Gallo CA, Plas DR, Biesiada J, Meller J, et
al: VHL-regulated miR-204 suppresses tumor growth through
inhibition of LC3B-mediated autophagy in renal clear cell
carcinoma. Cancer Cell. 21:532–546. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ran X, Yang J, Liu C, Zhou P, Xiao L and
Zhang K: MiR-218 inhibits HMGB1-mediated autophagy in endometrial
carcinoma cells during chemotherapy. Int J Clin Exp Pathol.
8:6617–6626. 2015.PubMed/NCBI
|
|
37
|
Sakitani K, Hirata Y, Hikiba Y, Hayakawa
Y, Ihara S, Suzuki H, Suzuki N, Serizawa T, Kinoshita H, Sakamoto
K, et al: Inhibition of autophagy exerts anti-colon cancer effects
via apoptosis induced by p53 activation and ER stress. BMC Cancer.
15:7952015. View Article : Google Scholar : PubMed/NCBI
|
